In a small randomized human trial, six months of a 12-ingredient supplement improved endothelial function, arterial-stiffness measures and arm systolic blood pressure. The results provide early evidence of an effect from the complete formula.
A 2026 randomized, double-blind, placebo-controlled human trial found that six months of daily NOVOS Core supplementation improved several measures of vascular function relative to placebo. The researchers enrolled 61 apparently healthy adults, 43 of whom completed assessments at baseline and six months.
Among those completers, the adjusted between-group difference in brachial-artery flow-mediated dilation, or FMD, was 2.9 percentage points, with a 95% confidence interval of 2.1 to 3.8. Pulse-wave velocity was 1.18 metres per second lower in the supplement group, while peripheral systolic blood pressure fell by 6.1 mmHg more than with placebo. Central systolic pressure and diastolic pressure did not show statistically detectable between-group effects, according to the full peer-reviewed trial report.
These findings concern vascular physiology rather than heart attacks, strokes or survival. That distinction matters because the product is marketed for longevity, while this trial measured intermediate cardiovascular markers over six months. NOVOS supplied the supplement and matching placebo and helped fund the study, as a LifeSpan.io report on the trial noted. The product-specific funding is relevant context, although the study incorporated random allocation, double blinding and a placebo control.
Three vascular measures shifted in the same direction
FMD evaluates how readily an artery widens in response to increased blood flow. During the test, a cuff temporarily restricts circulation in the arm. Ultrasound is then used to measure how much the brachial artery dilates after the cuff is released. The response reflects, in part, the ability of the endothelium—the cell layer lining blood vessels—to sense changing flow and signal the surrounding vessel wall to relax.
A higher FMD result generally indicates a stronger endothelial response. Its relevance to ageing is supported by cross-sectional human evidence: in a study of 457 healthy, nonsmoking adults aged 20 to 91, FMD was lower at older ages. Because that was an observational snapshot rather than an intervention, it documented an age-related pattern without showing that ageing alone caused the difference.
Pulse-wave velocity captures another aspect of vascular function. It measures how quickly a pressure wave travels through the arteries; faster transmission generally indicates a stiffer arterial system. The lower velocity measured after supplementation therefore points in the same favourable direction as the FMD finding, although neither measurement is itself a clinical outcome.
The blood-pressure result adds a familiar marker. Peripheral systolic pressure—typically measured in the arm—was lower relative to placebo, but the study did not detect corresponding effects on central systolic pressure or diastolic pressure. The three positive results are biologically coherent, yet each remains a surrogate or physiological measurement rather than evidence that the supplement prevents cardiovascular disease.
One formula, twelve possible contributors
NOVOS Core is not a single-compound intervention. The daily powder contains pterostilbene, glucosamine sulfate, fisetin, glycine, lithium aspartate, calcium alpha-ketoglutarate, magnesium malate, vitamin C, L-theanine, hyaluronic acid, Rhodiola rosea extract and ginger extract.
Testing the finished formulation answers a practical product-level question: does taking this particular mixture produce measurable changes compared with a matched placebo? It cannot show whether one ingredient drove the result, several acted additively, or interactions within the blend mattered. The researchers did not include mechanistic endpoints capable of resolving those possibilities.
The study examined both immediate and longer-term responses. Vascular function was assessed one hour after the first dose and again after six months. The final assessment took place approximately 24 hours after the most recent dose in an effort to reduce the influence of an immediate response. As the authors acknowledged, that interval cannot completely exclude a residual short-term effect.
This means the evidence applies most directly to the complete formulation, dose and schedule tested. It does not provide ingredient-specific support for buying one of the components separately, nor can benefits claimed for an individual ingredient be assumed to explain the trial’s findings.
A strong design met a small completer sample
Randomization and double blinding are important strengths in a supplement trial. They reduce the likelihood that expectations or baseline differences explain an observed effect, provided that the assigned groups remain adequately represented and blinding is maintained.
Here, however, 33 participants were assigned to the supplement and 28 to placebo, while only 43 completed both assessment visits. That loss matters because randomization balances groups at assignment; substantial attrition can weaken that protection if those who remain differ from those who leave. The small sample also leaves less room for random imbalances. The placebo group, for example, was older on average—a pertinent difference when endothelial function tends to vary with age.
The reported confidence intervals are therefore useful. For FMD, the interval from 2.1 to 3.8 percentage points indicates that the estimated difference was not being driven by a value barely distinguishable from zero. The intervals were wider for pulse-wave velocity and peripheral systolic pressure, reflecting greater uncertainty around the size of those effects.
Participants were generally healthy adults rather than people recruited for severe hypertension or established unstable cardiovascular disease. Average baseline blood pressure was in the 120s over approximately 75 mmHg. The result consequently should not be interpreted as a trial of treatment for hypertension or cardiovascular disease in a high-risk clinical population.
Duration also defines the claim. Six months is sufficient to identify a medium-term change in the measured vascular markers, but the trial was neither large enough nor long enough to test cardiovascular events. It also did not measure lifespan or establish an effect on biological ageing.
How to use the result without overstating it
For readers weighing longevity supplements, this trial is more informative than evidence limited to cells, animals or studies of isolated ingredients. It directly tested the marketed multi-ingredient formula in humans under blinded, placebo-controlled conditions, and several vascular measures moved in a consistent direction.
The narrowest accurate interpretation is also the most useful: among the adults who completed this six-month trial, the specific formulation improved endothelial responsiveness, reduced measured pulse-wave velocity and lowered peripheral systolic blood pressure relative to placebo. Those findings make the product’s vascular effects a legitimate subject for further clinical study.
They do not establish that the powder prevents heart attacks or strokes, and they cannot support a longevity claim. Demonstrating those outcomes would require substantially larger and longer trials designed around clinical events, with stronger participant retention. Further work would also need to determine whether the vascular changes persist and whether they are reproducible in people with different baseline cardiovascular risks.
The advance here is therefore concrete but bounded: placebo-controlled human evidence that one defined supplement blend can alter vascular surrogate markers over six months. That is relevant information for consumers and practitioners, provided it is read as evidence about the complete formula and measured vascular function—not as proof of extended life.